Dedicated to making life better for people living with underserved disorders with high unmet medical needs

Leveraging our proprietary fibroblast technology platform to create personalized therapies for localized treatments targeting the underlying cause of disease

Expanding our in-house cGMP operation to support a robust pipeline of innovative cell and gene therapies

Our focus on the patient drives everything we do and as a result, our path forward is clear:
to develop game-changing cell and gene therapies for localized treatment of underserved disorders with high unmet medical needs.

John Maslowski, Chief Executive Officer

Our robust development pipeline of personalized therapies for localized treatment

Applying the unique characteristics of autologous fibroblasts to create innovative cell and gene therapies

What's New

Media Coverage

Cell & Gene

Castle Creek Biosciences' D-Fi To Be Manufactured At In-House cGMP

Read More
Press Release

Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of D-Fi Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Company manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area

Read More
Media Coverage

Scleroderma News

First Patient Treated in Trial Testing FCX-013 Gene Therapy for Localized Scleroderma

Read More
Press Release

Castle Creek Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of FCX-013 Gene Therapy for Treatment of Moderate to Severe Localized Scleroderma

Study targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.

Read More